Quick Heal Technologies Ltd IPO Message Board (Page 48)

Latest GMP OF QHTL
APPLICATION RATE

Here is the link to the interview of QH management on CNBC

http://www.moneycontrol.com/news/ipo-issues-open/confidentupping-margins-maintaining-growth-pace_5356621.html

What is GMP???

GMP = Grey Market Premium = currently @70/-

Overall around 11%..

For those who r interested in knowing the subscription till 1450.

QIB- 0
NII- 0.0298
Ret- 0.1587
Emp- 0.0014

For BSE -

http://www.bseindia.com/markets/publicIssues/DisplayIPO.aspx?id=1053&type=IPO&idtype=1&status=L&IPONo=1128&startdt=2%2f8%2f2016

Refer BSE Demand schedule for recent (10 min lag) info.

eagleye please send link for Quick Heal BSE & NSE

How meny subscrib.. at this time???

Since 99 % retailers don''t have any knowledge of share market as such we should write to SEBI that bidding process for retailers should be limited to bidding for no. of shares at predetermined price as below:

1. In book building, the shares should be given at Lower band price. If the band is revised so should be the price for bidding price for retailers

2. In OFS, it should be the floor price

3. In fixed price IPOs, there should be a discount of at least 5% rounded off to whole number

If the Govt really wants to let larger participation of public in stock market, then they should listen to us. Public participation will stabilize the market.

Send physical letters in your own way to FM, SEBI & RBI

Eagle Eye

We should also ask the insurance companies to come up with a new innovative type of policy. Such policies should cover 200 to 300% of the loss in IPO if any incurred. Insurance Premium should be automatically covered/paid by the IPO releasing companies automatically for those retailers who subscribe to IPO.

This is win-win times 4 -) No loss will come ever in any IPO if this is implemented.

actual SEBI tried with Justdial issue had built in protection for retail investor...... it is very hard what is time frame many issue list at discount however over years have been multi bagger..... I like the free economy and we as investor should make the right choice..... I am a very long timer in IPO what i see is cycle few IPO come give handsome gain to RII this leads to many more IPOs hitting the market first all give return this leads to all applying in IPO then we get few bad listing faint hearted leave the IPO then IPO market is quiet then the cycle start again..... at least now SEBI has few guideline which filters bad IPOs..... last year 22 IPOs hit only 9 r making money this year will have 50 IPos 30 make money next year we 100 and hand few will make money then there will drop in IPO to single digit a year this has been happening for last 30 years

Read below link
1) https://bravostocks.wordpress.com/2015/10/11/quick-heal-ipo-worth-installing-or-removing/

it is asking P/E of about 40 whereas global peers are trading at P/E of 23.
Also remember global peers are about 50 times larger than Quick heal.

Also nowdays all OS are coming with inbuilt Antivirus. There is serious threat to its business. Also checked the interview of its management today and he could hardly speak properly or have any confidence going forward

A clear Avoid.

Wah Shivajee wah. Excellent write up. Not bad for a new bee.

Thank you Rajeev ji.Thanks for reading and appreciating, I need to learn a lot from you kind of people, septa ji, eagle eye, Davda sir, and others. I m only a part timer in share market, since markets alone are risky and have to take concentrate on work for day-to-day life needs. I don''t knw when I will reach the knowledge level that you all have!

Keep educating us so that we will at one point come up financially too!!

EAGLEYE... sir avoid ya apply quickheal

QHT GMP 74 - 76

Eagle Eye Sir Quick Heal Apply or Avoid

I am applying in QuickHeal

Any upcoming ipo on Feb month

6 ipo drawn back due to uncertainty

i will buy quick heal at rs 160 which is its fair price after listing if it reach that price

You are unlikely to see that price anytime soon

Poor subscription till 1230. 0.03 only.

No point tracking the subscription numbers for today & tomorrow ... everyone is waiting for ASBA release of Teamlease ... hence, the subscription will come only on last day

Very true. i am also waiting for ASBA release for my 6 account..!!

guys which are upcoming good ipo ?

What is the current Kostak price ?

500-550..BRO

sir pls tell quick heal me apply karna hai ya ignore karna hai ya nhi eagleye sir

QUICK HEAL TECH A HIGH VALUE STOCK MAY LIST AT DISCOUNT LIKE PCL

Quick Heal IPO – Some Facts & Figures

Product Quality – Average.
Based on the reviews as well as industry feedback, Quick Heal product quality for both, its Consumer as well as Enterprise segments seems to be average with no major differentiation vis-a-vis peers. This is key notable fact for its foray into overseas markets.

Sales Strategy – Excellent.
This is the key strength of the company – the way it sells its products – vis-a-vis its peers, even MNCs, Quick Heal is most aggressive in marketing its products as well as pushing its product via channel partners.

Domestic Market Positioning – Strong.
Company enjoys a very strong positioning in domestic market, especially in consumer segment.

Company''s Focus – SMEs, SOHO & Retail in Domestic Market & SMEs & SOHO in International Market.

Financials – Robust.
If we look at last 10 years'' financials, they seem exceptional with robust topline growth (10 Years'' CAGR = 53.26 %), albeit at a low base, and average EBITDA margin of 40 % + with average 50 % + EBITDA to Cash conversion.

Balance Sheet Strength – Above Average.
Although optically balance sheet does look strong with no debt and Cash & Cash Equivalents worth INR 142.24 cr., however, when we look this in the backdrop of Service Tax demand worth INR 62.73 cr. and Allowance for Doubtful Debts worth ~INR 41 cr. made over last two years, balance sheet strength seems above average.

Senior Management Quality Above Average

Board (BoD) Quality Above Average

Corporate Governance Standards Above Average


Summing Up All the factors :

Domestic market, especially consumer segment seems saturated and high topline growth reported by the company over last many years, which was on a low base, might not be possible on a higher base. Company seems to be very well aware of this and so has planned heavy expenditure on advertising over next three fiscals (60 cr., 70 cr. & 82 cr. p.a. respectively). Such aggressive promotion could let it sustain its strong positiong in domestic consumer segment.

Company is expecting majority of the future growth to come from enterprise segment which is evident from its stated guidance of making the consumer-enterpise segment ratio 50-50 in next few years from current 70-30. ''Seqrite'' is company''s enterprise segment brand via which it is targetting SMEs & SOHO.

Enterprise segment enjoys relatively lower margins in the range of 12-18 % vis-a-vis consumer segment''s 35-50 % margins. Hence, although historically company seems to have enjoyed average 40 % + EBITDA margins each year, rationale expectation should be maximum 25-35 % EBITDA margin going forward.

Another reason for lower EBITDA margin expectation is aggressive channel-push strategy adopted by the company for international market foray (company has reportedly offered profit margins of upto 50 % to its channel partners in North America). In addition, company might need to spend a realatively higher amount on R&D going forward becaof its focus on increasing enterprise segment sales.

Management seems to very well know its strength & weakness – weakness being its undifferentiated product in a crowded marketplace and strength being its sales & marketing stratey. Becaof likely saturation of company''s stronghold domestic consumer segment, management has aptly increased its focus on Enterprise Segment. However, Enterprise segment demands quality and heavy expenditure in R&D. This is the reason why management is targetting majorly SMBs & SOHOs in enterprise segment which have limited resources to spend and therefore demand ''Value for Money'' product by sometimes compromising on quality aspect.

However, focus on SMBs & SOHO via small/mediu m channel partners also means higher credit risks which is evident from last two years'' allowance for doubtful debts at INR 41 cr.

Shifting focus away from business as well as likely financials, If we look at the valuation aspect, then majority of M&A/PE deals done in the segment have been in the range of 11-15x EV/EBITDA and 3-9x EV/Sales. Even if we look at the available data of IPOs done in the segment internationally, then one IPO (AVG) was done at 14.89x EV/EBITDA, 6.09x EV/Sales and 18.39x P/E whereas the most recent IPO (Sophos) was done at 24.38x EV/EBITDA and 3.93x EV/Sales. At INR 321 per share, Quick Heal is offered at TTM EV/EBITDA (pure EBITDA excluding Other Income) of 22.53 and EV/Sales of 7.22 and P/E of 41.10 on post issue fully diluted equity capital.

Dear Eagleeye,

What do you suggest? Invest in quickheal?

QUICK HEAL IPO

GMP 75-80 @ AHMEDABAD

Qh ipo apply. ..
Yes/ no......
Please reaply. ...

Apply for med to long term.